Target intelligence / Profile preview

Serpin family A member 12 (SERPINA12)

Target
SERPINA12
Molecular classification
Serine protease inhibitor (serpin superfamily), Adipokine, Secreted protein
01

Overview

Serpin family A member 12 (SERPINA12), commonly called vaspin, is a secreted serine protease inhibitor predominantly produced in visceral adipose tissue. It functions as an adipokine and specifically inhibits the serine protease kallikrein 7, protecting insulin from degradation and thereby modulating insulin sensitivity and glucose homeostasis. Vaspin also interacts with the cell surface chaperone protein GRP78 (heat shock protein family A member 5), initiating intracellular signaling via AKT, AMPK, and MAPK pathways. SERPINA12 has established roles in lipid metabolism, inflammation, and may influence angiogenesis and cell proliferation. Dysregulation of SERPINA12/vaspin is associated with obesity, insulin resistance, type 2 diabetes, and several endocrine pathologies. Serum vaspin/ SERPINA12 concentrations are under investigation as biomarkers for metabolic diseases[1][2][3].

Other names
Serpin A12VaspinOL-64Visceral adipose tissue-derived serine protease inhibitorVisceral adipose-specific serpinserpin peptidase inhibitor clade A member 12
02

Mechanism of action

Inhibition of target serine proteases (especially kallikrein 7) to protect insulin from degradation and modulate metabolic homeostasis; Intracellular signaling modulation via binding to GRP78/Heat shock protein family A member 5 on the cell surface, activating kinase pathways.

03

Biological functions

Inhibition of serine proteases (notably kallikrein 7)Modulation of insulin sensitivity and glucose metabolismRegulation of lipid metabolismModulation of signal transductionNegative regulation of gluconeogenesisPositive regulation of cell signalingRegulation of lipid metabolic processes
04

Disease associations

ObesityInsulin resistanceType 2 diabetesInflammationPotentially cancer and cardiovascular disease via interaction with GRP78
05

Safety considerations

Therapeutic modulation remains experimental and could alter metabolic, inflammatory, and possibly proliferative pathways; functional redundancy and cross-reactivity within the serpin family may present risks
06

Biomarkers

Serum vaspin (SERPINA12) level as a potential biomarker for insulin resistance, metabolic syndrome, obesity, and related endocrine dysfunctions

Beyond the preview

Go deeper on Serpin family A member 12 (SERPINA12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serpin family A member 12 (SERPINA12).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call